Refine by
Drug Toxicity Articles & Analysis
29 news found
CD ComputaBio, a pioneering provider of computational biology services, has recently introduced its advanced Computer-Aided Drug Design (CADD) services, revolutionizing the drug discovery landscape. ...
The service predicts key parameters such as the interaction modes between molecules, including hydrogen bonds, van der Waals forces, and ionic bonds, as well as binding affinity and complementarity, to help clients better understand the mechanism of drug action and optimize drug molecule design and screening. Small molecule drug development ...
VeriSIM Life has developed a whole-body biosimulation platform driven by AI and machine learning (ML), that accurately predicts the clinical efficacy of new drugs before human trials. We are delivering strategic insights from our platform to translate, scale, and accelerate drug development to advance human health. ...
Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the acquisition of Cellesce Ltd (“Cellesce”) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening. Drug efficacy and toxicity ...
Traditionally, toxicity and safety evaluations of drugs are completed utilizing preclinical animal trials. In terms of PROTAC drug discovery and development, in vivo animal experiments can guide pilot optimizations to ensure low toxicity and better ADME performance. ...
Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development, today announced the publication of a peer-reviewed study in the Journal of Medicinal Chemistry. ...
This valuable public resource brings with it hope of reducing the major bottleneck in drug discovery: determining the mechanism of action for drug candidates. Other significant applications include predicting compounds’ activity and toxicity, as well as matching drugs to disease states. Ardigen’s primary scope of ...
ByArdigen
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...
The top priority for drug delivery research is to develop novel materials or carrier systems to achieve more effective therapeutic delivery of drugs. ...
STAR-LLD was well tolerated in all subjects with no drug-related toxicity or adverse events. The study enrolled a total of seventeen subjects across three escalating STAR-LLD dose cohorts, including 2.4mg/day, 4.8mg/day, and 9.6mg/day where each comparative SC dose was projected to be 48% of the oral Revlimid dose which ranged from 5 and 20 mg/day. ...
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that its ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) has escalated to the next planned dose. With no drug-limiting ...
Based on the persistence of cells in the peripheral blood and bone marrow up to 18 months we conclude that Temferon successfully engrafts, and no drug-limiting toxicities have been identified. The ability of Temferon cells to find their way from bone marrow to the tumor site is supported by the presence of gene-marked cells in the tumor resected specimens of the ...
To prevent graft rejection, transplanted patients are treated with lifelong immunosuppressive therapy, which impacts the body’s immune system and is associated with multiple side effects, including an increased risk of severe life-threatening infections, malignancies, cardiovascular disease, and other drug-related toxicities, such as nephrotoxicity, which ...
SERB and BTG Specialty Pharmaceuticals announced that the European Commission has granted marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. ...
“From comprehensive genomic inputs, the Cellworks Biosimulation Platform identifies pathway based polygenic biomarkers that predict the efficacy of novel drug combinations and new drugs for AML patients,” said Dr. Michael Castro, MD, Chief Medical Officer at Cellworks. ...
![[IB Tomato] (VC Portfolio) Villix, Containing the Identity of Reverse Idea and Novelty](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNTE1Ni9pbWFnZXMvMTI1MTU2XzBfMjAyMzAyMTUxMTQwMjgzNDM5NDg4XzQwMC5QTkciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MjQwLCJoZWlnaHQiOjE0NX19fQ== "[IB Tomato] (VC Portfolio) Villix, Containing the Identity of Reverse Idea and Novelty")
If you leave the empty part of the inner circle as it is, it becomes an anti-inflammatory treatment by itself, so if you put an anticancer drug in the empty space, it wraps around the anticancer drug without causing any chemical reaction. ...
SERB and BTG Specialty Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate ...
Maureen Bunger, Senior Product Manager, ADME-Tox Solutions, Lonza Cell and Gene, commented: “Today’s drug discovery success is hugely dependent on performing experiments using the right biological model to best reflect in vivo environments. ...
Ad Hoc Release Pursuant to Art. 53 Listing Rules Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring ...
StemBioSys, Inc., a privately held biomedical company that manufactures and develops innovative, advanced human stem cell technologies to improve the predictive power of pre-clinical drug safety screening, today announced its President and Chief Executive Officer Bob Hutchens will participate in Biotech Showcase Digital being held January 11-15, 2021. ...